Dr. Finn Discusses Research in Triple-Negative Breast Cancer
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses current research in triple-negative breast cancer (TNBC).
TNBC is an area of unmet need, Finn says, and is defined by the absence of a druggable target and represents many molecular subtypes in and of itself. Research has been conducted in TNBC looking at Src inhibition and PARP inhibition.
One PARP inhibitor, BMN 673, looks particularly potent for BRCA-mutated breast cancer. Still, Finn says, there remains a need to understand the biology of TNBC.